Shares of Teva Pharmaceutical Industries Ltd. advanced 3.3% in pre-market trading on Wednesday after the company reported positive Phase 2a clinical trial results for its investigational anti-interleukin-15 antibody, TEV '408, in celiac disease.
The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage at week 8 compared with a placebo. No safety concerns emerged during the study period, and the asset showed a favorable tolerability profile. TEV '408 is being co-developed with Royalty Pharma, which has committed up to $500 million to fund its clinical development.
Beyond celiac disease, TEV '408 is also advancing into a Phase 2b study for vitiligo, positioning it as a potential multi-indication therapy for autoimmune conditions. The positive readout follows a series of recent milestones for Teva, including a Moody's investment-grade credit upgrade, a U.S. FDA priority review designation for ecopipam in Tourette syndrome, and an upward revision to full-year revenue guidance. The stock has since approached its 52-week high.
U.S. equity futures showed modest gains ahead of the open, with the S&P 500 up 0.1%, the Dow Jones Industrial Average rising 0.3%, and the Nasdaq Composite edging 0.1% higher. Teva held an investor call this morning to discuss the clinical data and its broader pipeline strategy.
